NCT05625555View on ClinicalTrials.gov

Predictors of Intravenous Ketamine Response in TRD

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

February 28, 2025

Conditions
Treatment Resistant DepressionMajor Depressive DisorderBipolar Disorder
Interventions
DRUG

Ketamine

IV Ketamine infusion 0.5mg/kg over 40 minutes

DRUG

Midazolam

IV Midazolam infusion 30μg/kg over 40 minutes

Trial Locations (1)

B3H2E2

RECRUITING

Mood Disorders Program, Halifax

All Listed Sponsors
collaborator

Nova Scotia Health Authority

OTHER

lead

Abraham Nunes

OTHER

NCT05625555 - Predictors of Intravenous Ketamine Response in TRD | Biotech Hunter | Biotech Hunter